CoChat

Lovastatin and Rhabdomyolysis

Ayanian, John Z., Fuchs, Charles S., Stone, Richard M. · 1988 · Annals of Internal Medicine
Cited by 108

The DOI matches its Crossref record.

Abstract

Letters and Corrections15 October 1988Lovastatin and RhabdomyolysisJohn Z. Ayanian, MD, Charles S. Fuchs, MD, Richard M. Stone, MDJohn Z. Ayanian, MDSearch for more papers by this author, Charles S. Fuchs, MDSearch for more papers by this author, Richard M. Stone, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-109-8-682 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the Editor: Lovastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, the rate-limiting enzyme in cholesterol biosynthesis, lowers serum cholesterol in both familial (1) and nonfamilial (2) forms of hypercholesterolemia. Rhabdomyolysis, occasionally resulting in renal failure, has been reported in 13 patients receiving lovastatin therapy 9 of whom were also receiving cyclosporine or gemfibrozil therapy (3, 4). We report a case of severe rhabdomyolysis in a patient being treated with both lovastatin and erythromycin; the case potentially represents a new adverse drug interaction.A 65-year-old man with a history of severe coronary artery disease and chronic renal failure had been...References1. HavelHunninghakeIllingworth RDD Lovastatin (Mevinolin) in the treatment of heterozygous familial hypercholesterolemia. Ann Intern Med. 1987;107:609-15. LinkGoogle Scholar2. . Therapeutic response to lovastatin (mevinolin) in non-familial hypercholesterolemia. JAMA. 1986;256:2829-34. CrossrefMedlineGoogle Scholar3. NormanIllingworthMunson DDJ Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin. N Engl J Med. 1988;318:46-7. CrossrefMedlineGoogle Scholar4. EastAlivizatosGrundy CPS Rhadomyolysis in patients receiving lovastatin after cardiac transplantation. N Engl J Med. 1988;318:47-8. CrossrefMedlineGoogle Scholar5. Ludden T. Pharmacokinetic interactions of the macrolide antibiotics. Clin Pharmacokinet. 1985;10:63-79. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Brigham and Women's Hospital Harvard Medical School Boston, MA 02115 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited BySimvastatin Prevents Long-Term Cognitive Deficits in Sepsis Survivor Rats by Reducing Neuroinflammation and NeurodegenerationAmyotrophic Lateral Sclerosis Associated with Statin Use: A Disproportionality Analysis of the FDA’s Adverse Event Reporting SystemLovastatinMacrolide antibioticsInteracciones graves o potencialmente letales entre antirretrovirales y otros medicamentosCYP3A4: The WorkhorseOne pot synthesis of biologically active pregnane derivatives, their single crystal structures, spectroscopic characterization and theoretical calculationsUpdates on Cytochrome P450-Mediated Cardiovascular Drug InteractionsDrug Disposition and Drug–Drug Interactions: Importance of First-Pass Metabolism in Gut and LiverANTIBACTERIAL DRUGSUpdates on Cytochrome P450-Mediated Cardiovascular Drug InteractionsLIPID – REGULATING DRUGSSimvastatin-Associated Rhabdomyolysis After Coadministration of Macrolide Antibiotics in Two PatientsMacrolide antibioticsBench to Bedside: Pharmacogenomics, Adverse Drug Interactions, and the Cytochrome P450 SystemToxic MyopathiesComparative effects of lipid-lowering therapiesGenetic Polymorphisms in Cytochrome P450 EnzymesCombination lipid-lowering therapy with statins: safety issues in the postcerivastatin eraAntihyperlipidemic AgentsIatrogenic and toxic myopathiesChapter 32 Toxic myopathiesIssues in Hyperlipidemic PancreatitisA Study of the Interaction Potential of Azithromycin and Clarithromycin with Atorvastatin in Healthy VolunteersMyopathy and rhabdomyolysis with lipid-lowering drugs3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and rhabdomyolysis: considerations in the renal failure patientAcquired MyopathiesRhabdomyolysis and Satin Therapy: Relevance to the ElderlyPharmacokinetic-Pharmacodynamic Drug Interactions with HMG-CoA Reductase InhibitorsRhabdomyolysis and HMG-CoA Reductase InhibitorsStatin—Fibrate Combination TherapyThe role of cytochrome P450-mediated drug-drug interactions in determining the safety of statinsRhabdomyolysis Secondary to a Drug Interaction between Simvastatin and ClarithromycinSafety Profiles for the HMG-CoA Reductase InhibitorsDoes differing metabolism by cytochrome P450 have clinical importance?HMG-CoA Reductase Inhibitors: Assessing Differences in Drug Interactions and Safety ProfilesMacrolide Drug Interactions: An UpdatePharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 InhibitionNew insights into the pharmacodynamic and pharmacokinetic properties of statinsRhabdomyolysis and acute renal failure due to combination therapy with simvastatin and warfarinReview and Comparison of Advanced-Generation Macrolides Clarithromycin and

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7326/0003-4819-109-8-682

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 108

Metadata

Authors
Ayanian, J. Z., Fuchs, C. S., & Stone, R. M.
Venue
Annals of Internal Medicine
Published
1988-10-15
Volume
109
Issue
8
Pages
682-683
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W2017549231
Cited by
108
References
0
FWCI
6.70
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Lovastatin and Rhabdomyolysis. https://app.cochat.ai/papers/10.7326/0003-4819-109-8-682
The paper
Ayanian, J. Z., Fuchs, C. S., & Stone, R. M. (1988). Lovastatin and Rhabdomyolysis. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-109-8-682

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.